CN110099997A - 表达car和转录因子的细胞及其用途 - Google Patents

表达car和转录因子的细胞及其用途 Download PDF

Info

Publication number
CN110099997A
CN110099997A CN201780079674.7A CN201780079674A CN110099997A CN 110099997 A CN110099997 A CN 110099997A CN 201780079674 A CN201780079674 A CN 201780079674A CN 110099997 A CN110099997 A CN 110099997A
Authority
CN
China
Prior art keywords
ser
pro
leu
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780079674.7A
Other languages
English (en)
Chinese (zh)
Inventor
M.普勒
S.托马斯
S.科多巴
W.C.利姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otto Ruth Ltd
Original Assignee
Otto Ruth Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otto Ruth Ltd filed Critical Otto Ruth Ltd
Publication of CN110099997A publication Critical patent/CN110099997A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780079674.7A 2016-12-21 2017-12-20 表达car和转录因子的细胞及其用途 Pending CN110099997A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1621889.3 2016-12-21
GBGB1621889.3A GB201621889D0 (en) 2016-12-21 2016-12-21 Cell
PCT/GB2017/053834 WO2018115865A1 (en) 2016-12-21 2017-12-20 Cell expressing a car and a transcription factor and its use

Publications (1)

Publication Number Publication Date
CN110099997A true CN110099997A (zh) 2019-08-06

Family

ID=58284380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780079674.7A Pending CN110099997A (zh) 2016-12-21 2017-12-20 表达car和转录因子的细胞及其用途

Country Status (8)

Country Link
US (2) US20200030379A1 (https=)
EP (1) EP3559213A1 (https=)
JP (4) JP7149273B2 (https=)
CN (1) CN110099997A (https=)
AU (1) AU2017380449B2 (https=)
CA (1) CA3047621C (https=)
GB (1) GB201621889D0 (https=)
WO (1) WO2018115865A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805596A (zh) * 2021-01-22 2022-07-29 华东师范大学 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220127570A1 (en) * 2018-05-03 2022-04-28 Cafa Therapeutics Limited Immune effector cell and use thereof
WO2019243817A1 (en) * 2018-06-19 2019-12-26 Autolus Limited Cell
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
US20220169687A1 (en) 2020-11-10 2022-06-02 Kyverna Therapeutics, Inc. Method for treating disease using foxp3+cd4+ t cells
TW202239768A (zh) 2021-01-27 2022-10-16 美商萊爾免疫藥物股份有限公司 改良之免疫細胞療法
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
TW202246511A (zh) 2021-02-25 2022-12-01 美商萊爾免疫藥物股份有限公司 靶向ny-eso-1之增強免疫細胞療法
EP4347826A1 (en) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
IL312201A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing c-jun
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
EP4514363A4 (en) * 2022-04-25 2026-04-22 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR PREVENTING T LYMPHOCYTE DEPLETION
JP2025516823A (ja) 2022-05-19 2025-05-30 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３を標的とするポリヌクレオチド及びその使用
TW202413646A (zh) 2022-07-22 2024-04-01 美商萊爾免疫藥物股份有限公司 免疫細胞療法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193696A1 (en) * 2015-06-01 2016-12-08 Ucl Business Plc Cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2017035251A1 (en) * 2015-08-25 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-myb
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12060394B2 (en) * 2016-04-28 2024-08-13 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193696A1 (en) * 2015-06-01 2016-12-08 Ucl Business Plc Cell

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805596A (zh) * 2021-01-22 2022-07-29 华东师范大学 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用
CN114805596B (zh) * 2021-01-22 2023-07-14 华东师范大学 一种以磷脂酰肌醇聚糖3为靶点的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
AU2017380449A1 (en) 2019-06-13
US20240307440A1 (en) 2024-09-19
CA3047621C (en) 2024-01-02
JP2020511115A (ja) 2020-04-16
JP7149273B2 (ja) 2022-10-06
US20200030379A1 (en) 2020-01-30
AU2017380449B2 (en) 2023-01-05
WO2018115865A1 (en) 2018-06-28
JP2024133287A (ja) 2024-10-01
EP3559213A1 (en) 2019-10-30
JP2022145846A (ja) 2022-10-04
JP2024133286A (ja) 2024-10-01
CA3047621A1 (en) 2018-06-28
GB201621889D0 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
US20240307440A1 (en) Cell expressing a car and a transcription factor and its use
JP2024024014A (ja) 受容体
JP6929867B2 (ja) がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体
AU2017205637B2 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
CN108026151B (zh) Pd-1-cd28融合蛋白及其在医学中的用途
KR102235202B1 (ko) T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car)
JP2022502056A (ja) Ｓｓｘ２抗原を識別するｔ細胞受容体
JP7117304B2 (ja) 転写システム
CN105377886A (zh) 识别mage-a1的高亲和力结合分子
CN116731156A (zh) 用于癌症免疫治疗的转染t细胞和t细胞受体
KR20250058773A (ko) 키메라 항원 수용체 및 이의 용도
WO2019053420A1 (en) CELL
CN113195527A (zh) Tcr和肽
CN113195526B (zh) 针对过继性t细胞疗法中的突变myd88l265p蛋白表位的特异性t细胞受体
JP2021531834A (ja) Ａｆｐ抗原を識別するｔ細胞受容体
CN115466331B (zh) 靶向bcma的嵌合抗原受体及其应用
KR102381854B1 (ko) T 세포 수용체 및 이를 사용하는 면역 요법
CN111954813A (zh) 工程化细胞溶解性免疫细胞
KR20240095172A (ko) 항원 특이적 t 세포 수용체 및 키메라 공동자극 수용체의 조합
CN117304301A (zh) 一种结合ssx2抗原的tcr分子及其应用
CN115677847A (zh) 一种识别ssx2的t细胞受体及其编码序列

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination